Alternatively, on the basis of specific SOCE features, such as the SOCE dependence on Orai3 in ER+ breast [83] or the up-regulation of TRPC6 and its specific role in Orai1/Orai3 plasma membrane expression in the MCF-7 and MDA-MB-231 cell lines [82], Orai3 or TRPC6 might be established as potential selective therapeutic targets for breast cancers. This evidence concerns the gene ORAI1 and breast carcinoma.